Raymond James reiterated their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a research report sent to investors on Thursday morning, BayStreet.CA reports. Raymond James currently has a C$10.25 price target on the stock.

Shares of GUD stock opened at C$7.55 on Thursday. The company has a 50 day moving average of C$7.57. Knight Therapeutics has a twelve month low of C$7.10 and a twelve month high of C$8.76. The stock has a market cap of $1.08 billion and a P/E ratio of 48.40. The company has a quick ratio of 31.73, a current ratio of 32.29 and a debt-to-equity ratio of 0.10.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, May 9th. The company reported C$0.04 earnings per share for the quarter, beating the consensus estimate of C$0.03 by C$0.01. The company had revenue of C$2.96 million during the quarter, compared to analysts’ expectations of C$3.06 million. Research analysts expect that Knight Therapeutics will post 0.15 EPS for the current year.

In other Knight Therapeutics news, insider Long Zone Holdings Inc. purchased 12,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were purchased at an average cost of C$7.59 per share, for a total transaction of C$91,080.00. Following the completion of the purchase, the insider now directly owns 21,633,433 shares in the company, valued at C$164,197,756.47. Also, Director Robert Nathaniel Lande purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was acquired at an average price of C$7.52 per share, for a total transaction of C$150,300.00. Following the completion of the purchase, the director now owns 45,392 shares of the company’s stock, valued at C$341,120.88. Over the last 90 days, insiders purchased 42,000 shares of company stock worth $315,280.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Story: What are Bollinger Bands?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.